-
公开(公告)号：US20170340720A1
公开(公告)日：2017-11-30
申请号：US15589834
申请日：2017-05-08
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Fabio BAGNOLI , Massimiliano BIAGINI , Luigi FIASCHI , Guido GRANDI , Ravi Pratap Narayan MISHRA , Nathalie NORAIS , Maria SCARSELLI
IPC: A61K39/085 , C07K14/31 , A61K39/00
CPC classification number: A61K39/085 , A61K39/00 , C07K14/31 , C07K2319/00
Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
-
公开(公告)号：US20180298064A1
公开(公告)日：2018-10-18
申请号：US16019365
申请日：2018-06-26
Inventor： Vega MASIGNANI , Danilo Gomes MORIEL , Francesco BERLANDA SCORZA , Nathalie NORAIS , Maria Rita FONTANA , Mariagrazia PIZZA , Laura SERINO , Hervé TETTELIN
IPC: C07K14/245 , A61K39/108 , C07K16/12
Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
-
公开(公告)号：US20180009852A1
公开(公告)日：2018-01-11
申请号：US15698434
申请日：2017-09-07
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Jeannette ADU-BOBIE , Mariagrazia PIZZA , Nathalie NORAIS , Germano FERRARI , Guido Grandi
IPC: C07K14/245 , A61K39/095 , C12N9/10 , C07K14/22 , A61K39/00 , A61K39/108
CPC classification number: C07K14/245 , A61K39/00 , A61K39/0258 , A61K39/095 , C07K14/22 , C12N9/1051 , Y02A50/474
Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.
-
4.发明申请PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI 审中-公开来自MENINGITIS / SEPSIS相关的ESCHERICHIA COLI的蛋白质和核酸公开(公告)号：US20160244489A1
公开(公告)日：2016-08-25
申请号：US15150204
申请日：2016-05-09
Inventor： Vega MASIGNANI , Danilo Gomes MORIEL , Francesco BERLANDA SCORZA , Nathalie NORAIS , Maria Rita FONTANA , Mariagrazia PIZZA , Laura SERINO , Herve TETTELIN
IPC: C07K14/245 , A61K39/108 , C07K16/12
CPC classification number: C07K14/245 , A61K39/00 , A61K39/0258 , A61K2039/505 , A61K2039/523 , C07K16/1232
Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
Abstract translation: 本文公开了来自负责新生儿脑膜炎（MNEC）的大肠杆菌菌株的各种开放阅读框，以及对于制备用于免疫MNEC感染的组合物特别有意义的这些的一部分。
-
公开(公告)号：US20160158335A1
公开(公告)日：2016-06-09
申请号：US14961772
申请日：2015-12-07
Applicant: GlaxoSmithKline Biologicals SA
Inventor： Fabio BAGNOLI , Massimiliano BIAGINI , Luigi FIASCHI , Guido GRANDI , Ravi Pratap Narayan MISHRA , Nathalie NORAIS , Maria SCARSELLI
IPC: A61K39/085 , C07K14/31
CPC classification number: A61K39/085 , A61K39/00 , C07K14/31 , C07K2319/00
Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.
Abstract translation: 有效的金黄色葡萄球菌疫苗可能需要几种抗原成分，因此鉴定出金黄色葡萄球菌抗原的各种组合用于免疫。 这些多肽可以任选地与金黄色葡萄球菌组合使用。
-
Patent Agency Ranking
公开(公告)号：US20230266317A1
公开(公告)日：2023-08-24
申请号：US17641315
申请日：2020-09-09
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Michael CHAPLET , Nathalie NORAIS , Simona RONDINI , Silvia ROSSI PACCANI
IPC: G01N33/569 , C07K16/12
CPC classification number: G01N33/56911 , C07K16/1203 , G01N2333/212 , C07K2317/33
Abstract: The present invention relates to in vitro assays, more particularly ELISA assays. Said ELISA assays comprise antibodies capable of binding Ubiquitous surface protein A2 (UspA2) from Moraxella catarrhalis. The present invention relates to assays for assessing the binding of antibodies to UspA2 and the relative potency of vaccine test samples comprising UspA2. In particular, the invention relates to in vitro relative potency assays used in the release of vaccine that comprises UspA2 to the public.
-
公开(公告)号：US20220257751A1
公开(公告)日：2022-08-18
申请号：US17628667
申请日：2020-07-21
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Massimilliano BIAGINI , Lucia Eleonora FONTANA , Anna GALEA , Nathalie NORAIS , Maria SCARSELLI
IPC: A61K39/385 , C07K14/205 , C07K14/21 , C07K14/22 , C07K14/245 , C07K14/31 , C07K14/33 , C12P21/00 , C12Q1/37 , G01N33/68
Abstract: The present invention provides analytical tools for the characterisation of bioconjugates, in particular for the measurement of glycosylation levels, and methods for absolute quantification of glycosylation sequences, as well as sequences and glycosylation sites for use in such methods.
-
公开(公告)号：US20220221455A1
公开(公告)日：2022-07-14
申请号：US17604008
申请日：2020-04-16
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Nathalie NORAIS , Silvia ROSSI PACCANI , Simona RONDINI
IPC: G01N33/569
Abstract: The present invention relates to the field of antigen binding proteins and the use of such antigen binding proteins in an assay. More particularly, it relates to antigen binding proteins which bind to an epitope of Protein E and antigen binding proteins which bind to an epitope of PilA. The present invention also relates to assays (particularly in vitro assays) for assessing binding to Protein E and/or PilA and the potency of vaccines containing Protein E and/or PilA. In particular the invention relates to in vitro relative potency assays used in the release of a vaccine to the public.
-
公开(公告)号：US20190290748A1
公开(公告)日：2019-09-26
申请号：US16363799
申请日：2019-03-25
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Marco SORIANI , Maria SCARSELLI , Nathalie NORAIS , Danilo GOMES MORIEL , Silvia ROSSI PACCANI
IPC: A61K39/102 , C07K14/285 , C12R1/21 , A61K39/02 , A61K39/095
Abstract: NTHI protein antigens have been identified and found to be conserved across several Haemophilus influenzae pathogenic strains. They have been isolated, cloned from a reference strain and tested for immunogenicity. Methods for immunization and vaccines derived thereof are also disclosed.
-
公开(公告)号：US20160108094A1
公开(公告)日：2016-04-21
申请号：US14927052
申请日：2015-10-29
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Jeannette ADU-BOBIE , Mariagrazia PIZZA , Nathalie NORAIS , Germano FERRARI , Guido GRANDI
IPC: C07K14/245 , C07K14/22
CPC classification number: C07K14/245 , A61K39/00 , A61K39/0258 , A61K39/095 , C07K14/22 , C12N9/1051 , Y02A50/474
Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.
Abstract translation: 脑膜炎球菌mltA同系物的敲除使细菌自发释放富含免疫原性外膜蛋白的囊泡，并且能够以比正常生产过程制备的OMV更高的杀菌滴度引发交叉保护性抗体应答。 因此，本发明提供了具有其mltA基因的敲除突变的细菌。 本发明还提供了一种细菌，其中所述细菌：（i）具有包含肽聚糖的细胞壁; 和（ii）不表达具有溶解性转糖苷酶活性MltA蛋白质的蛋白质。 本发明还提供包含囊泡的组合物，其在本发明的细菌培养期间释放到培养基中。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.025 seconds)
